Celsion (NASDAQ: CLSN) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Celsion to similar companies based on the strength of its valuation, earnings, risk, profitability, dividends, analyst recommendations and institutional ownership.
Volatility and Risk
Celsion has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, Celsion’s competitors have a beta of 0.88, indicating that their average share price is 12% less volatile than the S&P 500.
This table compares Celsion and its competitors’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a breakdown of recent recommendations and price targets for Celsion and its competitors, as reported by MarketBeat.com.
||Strong Buy Ratings
Celsion presently has a consensus target price of $14.50, suggesting a potential upside of 475.40%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.63%. Given Celsion’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Celsion is more favorable than its competitors.
Earnings and Valuation
This table compares Celsion and its competitors revenue, earnings per share and valuation.
Celsion’s competitors have higher revenue and earnings than Celsion. Celsion is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
4.2% of Celsion shares are held by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 3.8% of Celsion shares are held by insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Celsion Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).
Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.